Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
MONTELUKAST SODIUM
Merck Sharp and Dohme Limited
5 Milligram
Tablets Chewable
1998-02-20
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Singulair Paediatric 5 mg chewable tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One chewable tablet contains montelukast sodium, which is equivalent to 5 mg montelukast. Excipient: Aspartame (E 951) 1.5 mg per tablet. _For a full list of excipients, see section 6.1._ 3 PHARMACEUTICAL FORM Chewable tablet Pink, round, biconvex, diameter 9.5 mm with SINGULAIR engraved on one side, MSD 275 on the other. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS SINGULAIR is indicated in the treatment of asthma as add-on therapy in those patients with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom “as -needed” short acting - agonists provide inadequate clinical control of asthma. SINGULAIR may also be an alternative treatment option to low-dose inhaled corticosteroids for patients with mild persistent asthma who do not have a recent history of serious asthma attacks that required oral corticosteroid use, and who have demonstrated that they are not capable of using inhaled corticosteroids _(see section 4.2)._ SINGULAIR is also indicated in the prophylaxis of asthma in which the predominant component is exercise-induced bronchoconstriction. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION The dosage for pediatric patients 6-14 years of age is one 5-mg chewable tablet daily to be taken in the evening. If taken in connection with food, SINGULAIR should be taken 1 hour before or two hours after food. No dosage adjustment within this age group is necessary. _General recommendations. _The therapeutic effect of SINGULAIR on parameters of asthma control occurs within one day. Patients should be advised to continue taking SINGULAIR even if their asthma is under contr Read the complete document